Interojo (119610) Fundamentals 2026 — P/E 9.9x, Revenue Analysis | SniperIQ
Interojo (119610) is a KR-listed Healthcare company in Medical - Instruments & Supplies with a market capitalization of ₩158.3B, trading at ₩14090.00 on the KOE. This SniperIQ fundamentals page covers Interojo's valuation (P/E 9.9x, P/B 1.0x), profitability (net margin 13.1%), revenue (₩118.5B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Interojo's market cap?
Interojo (119610) has a market capitalization of approximately ₩158.3B, trading at ₩14090.00 on the KOE. Market cap moves with the live share price.
What is Interojo's P/E ratio?
Interojo's trailing twelve-month P/E ratio is 9.9x, with a price-to-book (P/B) of 1.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Interojo?
Interojo runs a net profit margin of 13.1%, a gross margin of 36.6%, and an operating margin of 18.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Interojo generate?
Interojo reported revenue of ₩118.5B for fiscal year 2025, with net income of ₩13.0B and earnings per share (EPS) of 1139.11. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Interojo pay a dividend?
Interojo offers a trailing dividend yield of about 4.6%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Interojo financially healthy?
Interojo carries a debt-to-equity ratio of 0.37x and a current ratio of 2.31x, with a market beta of 0.33. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Interojo a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Interojo (119610) the key facts are: market cap ₩158.3B, P/E 9.9x, revenue ₩118.5B, 52-week range 13900-23100. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Interojo's full fundamentals live
Get Interojo's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.